Drug news
Olesoxime(Trophos S.A.) fails Phase III trial for ALS
Olesoxime from Trophos S.A. failed to show an increase in survival compared to placebo in patients receiving Rilutek (riluzole) in its Phase III trial for Amyothrophic Lateral Sclerosis (ALS),often known as "Lou Gehrig's Disease". Actelion has withdrawn from its option to acquire the shares of Trophos S.A. and the company has announced that it will concentrate on other indications for the drug which includes spinal muscular atrophy.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.